State Street Corp Otonomy, Inc. Transaction History

State Street Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$1.72 - $2.47 $15,203 - $21,832	8,839 Added 5.1%	182,239 $437,000
Q2 2021 Aug 16, 2021	BUY	$2.06 - $2.67 $268,438 - $347,927	130,310 Added 302.41%	173,400 $387,000
Q4 2020 Feb 16, 2021	BUY	$3.48 - $6.47 $149,953 - $278,792	43,090 New	43,090 $279,000
Q3 2020 Nov 10, 2020	SELL	$3.16 - $4.36 $109,304 - $150,812	-34,590 Closed	0 $0
Q1 2020 May 11, 2020	BUY	$1.58 - $4.06 $54,652 - $140,435	34,590 New	34,590 $68,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.